GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ViroPharma, Inc. (FRA:VPH) » Definitions » Cyclically Adjusted Revenue per Share

ViroPharma, (FRA:VPH) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is ViroPharma, Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ViroPharma,'s adjusted revenue per share for the three months ended in Sep. 2013 was €1.179. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Sep. 2013.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-22), ViroPharma,'s current stock price is €36.08. ViroPharma,'s Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2013 was €0.00. ViroPharma,'s Cyclically Adjusted PS Ratio of today is .


ViroPharma, Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for ViroPharma,'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroPharma, Cyclically Adjusted Revenue per Share Chart

ViroPharma, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ViroPharma, Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ViroPharma,'s Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, ViroPharma,'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroPharma,'s Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ViroPharma,'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ViroPharma,'s Cyclically Adjusted PS Ratio falls into.



ViroPharma, Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ViroPharma,'s adjusted Revenue per Share data for the three months ended in Sep. 2013 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=1.179/98.7900*98.7900
=1.179

Current CPI (Sep. 2013) = 98.7900.

ViroPharma, Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200312 0.033 77.758 0.042
200403 0.054 79.066 0.067
200406 0.055 80.037 0.068
200409 0.012 80.121 0.015
200412 0.516 80.290 0.635
200503 0.396 81.555 0.480
200506 0.414 82.062 0.498
200509 0.489 83.876 0.576
200512 0.566 83.032 0.673
200603 0.347 84.298 0.407
200606 0.498 85.606 0.575
200609 0.618 85.606 0.713
200612 0.412 85.142 0.478
200703 0.517 86.640 0.590
200706 0.498 87.906 0.560
200709 0.437 87.964 0.491
200712 0.389 88.616 0.434
200803 0.389 90.090 0.427
200806 0.499 92.320 0.534
200809 0.543 92.307 0.581
200812 0.413 88.697 0.460
200903 0.596 89.744 0.656
200906 0.657 91.003 0.713
200909 0.620 91.120 0.672
200912 0.778 91.111 0.844
201003 0.745 91.821 0.802
201006 0.990 91.962 1.064
201009 0.998 92.162 1.070
201012 1.015 92.474 1.084
201103 0.944 94.283 0.989
201106 0.999 95.235 1.036
201109 1.191 95.727 1.229
201112 1.308 95.213 1.357
201203 1.209 96.783 1.234
201206 1.087 96.819 1.109
201209 1.045 97.633 1.057
201212 1.151 96.871 1.174
201303 1.269 98.209 1.277
201306 1.141 98.518 1.144
201309 1.179 98.790 1.179

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


ViroPharma,  (FRA:VPH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ViroPharma, Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of ViroPharma,'s Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroPharma, (FRA:VPH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ViroPharma, Inc. (FRA:VPH) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
N/A
Address
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.

ViroPharma, (FRA:VPH) Headlines

No Headlines